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Abstract Better understanding of the pathogenesis and treat-
ment of primary systemic vasculitides (PSV) has led to the
development of many potentially clinically relevant bio-
markers. Genome-wide association studies have highlighted
that MHC class II polymorphisms may influence the develop-
ment of particular anti-neutrophil cytoplasmic antibody
(ANCA) serotypes, but not the clinical phenotype of
ANCA-associated vasculitis (AAV). Although ANCAs are
overall poor biomarkers of disease activity, theymay be useful
for the prediction of flares of renal and/or pulmonary vasculi-
tis. Moreover, patients with proteinase 3 (PR3)-AAV may re-
spond better to rituximab than cyclophosphamide. Newer bio-
markers of renal vasculitis in AAV include urinary soluble
CD163, and may in the future reduce the requirement for renal
biopsy. Better understanding of dysregulated neutrophil acti-
vation in AAV has led to the identification of novel bio-
markers including circulating microparticles, and neutrophil
extracellular traps (NETs), although their clinical utility has
not yet been realised. Studies examining endothelial injury
and repair responses have additionally revealed indices that
may have utility as disease activity and/or prognostic bio-
markers. Last, next-generation sequencing technologies are
revealing monogenic forms of vasculitis, such as deficiency
of adenosine deaminase type 2 (DADA2), and are profoundly
influencing the approach to the diagnosis and treatment of
vasculitis in the young.
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Introduction
This review summarises recent advances in our understanding
of the pathophysiology of primary systemic vasculitides
(PSV), and consequently, the potential role of novel bio-
markers discovered in that context. The diseases considered
are those where renal vasculitis is of particular concern, name-
ly the anti-neutrophil cytoplasmic antibody (ANCA)-associ-
ated vasculitides (AAV), and IgA vasculitis (IgAV; Henoch–
Schönlein purpura, HSP). A brief mention of other forms of
PSV, and of treatment, will be made only in the context of
more general comments in relation to pathophysiology and
biomarkers. For recent reviews and guidance in relation to
treatment, the reader is referred to Eleftheriou and Brogan,
Ntatsaki et al. and Yates et al. [1–3].
What is a biomarker, and what is it a biomarker of?
A biomarker is defined as any characteristic that is objectively
measured and evaluated as an indicator of normal biological
processes, pathogenic processes, or pharmacological re-
sponses to a therapeutic intervention [4]. An equally important
and clinically relevant question regarding biomarkers is Ba
biomarker of what?^ In the context of PSV, biomarkers may
have clinical utility for different non-mutually exclusive areas
including: predisposition to vasculitis; diagnosis; prediction of
disease flare; disease activity; prognosis; and/or choice of
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therapy. With this framework in mind, particular clinical is-
sues where biomarkers and/or new genetic tests could help
include: diagnostic tests to robustly identify important clinical
phenotypes of vasculitis (for epidemiological studies and/or
clinical trials), e.g. identifying novel genetic diagnostic tests
for monogenic vasculitides, or for distinguishing between mi-
croscopic polyangiitis (MPA) and granulomatosis with poly-
angiitis (GPA); prediction of disease flares and/or identifica-
tion of subjects at risk of frequent flares; biomarkers of disease
activity to help guide treatment duration and optimal timing of
stoppingmedication; prognosis, particularly in relation to sub-
jects with a bad renal prognosis who could be targeted for
more aggressive treatment; and to guide choice of therapy
(e.g. cyclophosphamide versus rituximab for induction of re-
mission). A description of recent studies examining pathogen-
esis and/or revealing novel genes and biomarkers of PSV that
are beginning to address some of these important areas, or
which provide a better understanding of biomarkers already
in clinical use, is provided. It should be noted, however, that
many of the studies cited (particularly in relation to AAV) deal
with studies largely involving adult patients, and this impor-
tant caveat must be considered when extrapolating the find-
ings to paediatric patients.
ANCA-associated vasculitides
The AAVs include: granulomatosis with polyangiitis (GPA),
most commonly associated with proteinase 3 (PR3)-ANCA,
although myeloperoxidase (MPO)-ANCAs are present in a
minority; microscopic polyangiitis (MPA), typically associat-
ed with MPO-ANCA; single organ disease, including renal-
limited vasculitis (again mainly associated with MPO-
ANCA); and eosinophilic granulomatous polyangiitis
(EGPA) [5]. As most children with EGPA are in fact
ANCA-negative [5, 6], EGPA is not considered further in this
review, and the reader is referred elsewhere for a recent de-
scription of this entity in children [6].
Clinical features of AAV
From a clinical perspective, it may be useful to think of GPA
as having two forms: a predominantly granulomatous form
with mainly localised disease with a chronic course; and a
florid, Btrue^ acute small vessel vasculitic form characterised
by severe pulmonary haemorrhage and/or rapidly progressive
vasculitis or other severe vasculitic manifestation [7]. These
two broad pathogenic processes may co-exist or present se-
quentially in individual paediatric/adult patients alike. In a
series of 17 children with GPA, the frequency of different
system involvement was: respiratory 87%, renal 53%, ENT
35%, musculoskeletal 53%, eyes 53%, nervous system 12%,
and skin 53% [8]. Another paediatric series of GPA reported
an even higher frequency of renal involvement, with 22 out of
25 patients who had glomerulonephritis at first presentation,
and only 1 out of 11 patients who had renal impairment in that
series recovered renal function with therapy [9]. Cabral et al.
described 65 children with GPA reporting renal involvement
in up to 75.4% of cases [10]. Dialysis was necessary in 7
patients (10.8%), and end-stage renal disease was present in
a single patient of that series [10]. In adult patients, data sug-
gest that approximately 73.5% of adults with GPAmight have
histological evidence of glomerulonephritis [11]. Of note, re-
nal involvement in GPA accrues with increasing disease du-
ration, which could account in part for the variation in reported
renal involvement in paediatric GPA. Similar distribution of
symptoms and organ involvement was noted in the cases sub-
mitted for the validation exercise of the European League
Against Rheumatism/Paediatric Rheumatology International
Trials Organisation/Paediatric Rheumatology European
Society (EULAR/PRES/PRINTO) paediatric vasculitis classi-
fication criteria [12]. Comparing the paediatric and adult co-
horts, although organ involvement, signs and symptoms are
similar, there are differences in their frequencies at disease
presentation; in general, adult patients have lower frequencies
of constitutional symptoms (fever, weight loss), certain ENT
features (oral/nasal ulceration, chronic or recurrent otitis
media/aural discharge), respiratory (tracheal/endobronchial
stenosis, obstruction, haemoptysis/alveolar haemorrhage),
and renal (haematuria or red blood cell casts) involvement;
and a higher frequency of conductive hearing loss than chil-
dren [11, 13].
The typical clinical manifestations of MPA are rapidly pro-
gressive glomerulonephritis and alveolar haemorrhage, al-
though virtually any organ system can be affected [7, 14]. In
adults, 75–80% of patients have detectable peri-nuclear
(p)ANCA/MPO-ANCA. MPO-ANCA pathogenicity has
been established in animal models, and trans-placental trans-
mission to a neonate has been described (see below). Renal
limited forms of MPA are described in children and adults [7].
Despite the classic description that MPA mainly affects the
kidneys and lungs, other organ involvement can occur and
clinicians should be alert to this (7;14).
Pathogenesis of AAV: how do ANCAs cause vasculitis?
A considerable body of evidence supports the concept that
ANCAs are directly involved in the pathogenesis of small
vessel vasculitis [15]. The most compelling human evidence
relates to reports of a neonate who developed pulmonary renal
syndrome soon after birth from the trans-placental transfer of
IgG MPO-ANCA from the mother, who had active micro-
scopic polyangiitis (MPA) [16, 17]. Moreover, mouse models
show that the passive transfer of MPO-ANCA or anti-MPO
lymphocytes (that make MPO-ANCA) into mice that lack
functioning B or T cells (RAG −/−) resulted in pauci-
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immune crescentic nephritis and small vessel vasculitis simi-
lar to that observed in humans with AAV [18]. Evidence of
direct pathogenicity of human PR3-ANCA had hitherto been
lacking. Progress in the study of these antibodies in rodents
was hampered by lack of PR3 expression on murine neutro-
phils, and by different Fc-receptor affinities for IgG across
species. Thus, Little et al. tested whether human anti-PR3
antibodies could induce vasculitis in mice with a human im-
mune system [19]. Chimeric mice were treated with human
IgG from patients with: anti-PR3 positive renal and lung vas-
culitis; patients with non-vasculitic renal disease; or healthy
controls. Six-days later, 39% of anti-PR3-treated mice had
clinical evidence of vasculitis, which was confirmed histolog-
ically. Specifically, anti-PR3-treated mice had evidence of
pauci-immune proliferative glomerulonephritis, with infiltra-
tion of human and mouse leucocytes [19], providing evidence
for the first time that human IgG from patients with anti-PR3
autoantibodies was pathogenic.
A plethora of publications describe in detail the mech-
anism of vascular injury mediated by ANCA, and these
have been eloquently summarised previously [15, 20, 21].
The most accepted model of pathogenesis proposes that
ANCAs activate cytokine-primed neutrophils, leading to
bystander damage of endothelial cells and an escalation of
inflammation with recruitment of mononuclear cells [15,
20, 21]. Neutrophil priming involves stimulation with an
agent, such as lipopolysaccharide (LPS) or the cytokine
tumour necrosis factor alpha (TNF-α), at a concentration
that does not of itself cause full functional activation, but
rather results in the translocation of ANCA-antigen (MPO
and/or PR3) from intracellular granules to the cell surface
[22]. Subsequent ANCA activation of these primed neu-
trophils leads to a respiratory burst and degranulation,
thereby generating the potential for endothelial injury.
The binding of ANCAs to antigens expressed on the sur-
face of primed neutrophils is not enough in itself to cause
full neutrophil activation; the binding of Fc receptors is
also necessary [23]. Following neutrophil stimulation by
ANCAs, numerous cytotoxic mediators are released, in-
cluding reactive oxygen species, chemokines, cytokines,
proteolytic enzymes and nitric oxide (NO) [15, 20, 21].
The firm adhesion of activated neutrophils to endothelial
cells results in endothelial cell damage and perhaps re-
cruitment of other inflammatory cells including mono-
cytes and T cells [15, 20, 21]. Following neutrophil acti-
vation by ANCA, neutrophils are driven down an accel-
erated, but aberrant apoptotic pathway. Thus, the neutro-
phils develop the morphological features of apoptosis, but
there is a failure in cell surface changes, such as bi-lipid
cellular membrane phosphatidylserine (PS) externalisa-
tion, which is normally an early feature of all apoptotic
cells. This lack of PS externalisation means that phago-
cytes are less able to process the apoptotic neutrophils in a
non-phlogistic fashion, explaining the well-characterised
finding of leucocytoclasis that is often seen in the vascu-
litic lesions of certain vasculitic syndromes [24].
Thus, it is clear that ANCAs are directly pathogenic, but
why do patients make ANCAs in the first instance?
Genetic predisposition determines ANCA serotype but not
clinical phenotype
Although it had long been proposed that patients with AAV
had a genetic predisposition to developing the disease, con-
vincing data in support of that were lacking [24]. In recent
years, the genetic factors predisposing to ANCA development
are better understood. The first ever genome-wide association
study (GWAS) involved 1,233 patients from the UK with
AAV; 5,884 controls; and a replication cohort of 1,454 AAV
cases from Northern Europe, and 1,666 controls [25]. The
strongest genetic associations were with the antigenic speci-
ficity of ANCAs, not with the clinical subtype of AAV. PR3-
ANCAwas associated with HLA-DP and the genes encoding
alpha(1)-antitrypsin (SERPINA1, the main inhibitor of PR3),
and the gene encoding PR3 itself (PRTN3). In contrast, MPO-
ANCA was associated with HLA-DQ. This study thus con-
firmed that the pathogenesis of ANCA-associated vasculitis
has a genetic component, shows genetic distinctions between
GPA and MPA in terms of the ANCA serotype, but not the
phenotype of AAV per se [25]. Other genetic polymorphisms,
such as CTLA4 and PTPN22 (and probably many others) are
also likely to be contributory [26]. Even though these studies
provide insight into the pathogenesis of the breakdown of
immune tolerance in patients with AAV, the strength of these
associations neither allows these genetic polymorphisms to be
used to identify high-risk populations that could be targeted
for screening, nor can they be used for the diagnosis of vas-
culitis, to determine prognosis, or choice of therapy.
Gene expression profiles may identify patients at risk
of relapsing AAV
Even though the aforementioned single nucleotide polymor-
phisms detected using GWAS have little clinical utility as
biomarkers, gene expression profiling may identify patients
with AAV at risk of relapsing disease. McKinney et al. dem-
onstrated that transcriptional profiling of purified CD8 T cells
identified two distinct subject patient subgroups predicting
long-term prognosis in AAV, and systemic lupus erythemato-
sus (SLE) [27]. The subset of genes defining the poor prog-
nostic group was enriched for genes involved in the
interleukin-7 receptor (IL-7R) pathway, T cell receptor
(TCR) signalling, and those expressed by memory T cells
[27]. These subgroups were also found in the normal
(healthy) population, and could be identified by measuring
the expression of only three genes: ITGA2, NOTCH1, and
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(the aforementioned gene) PTPN22. Although the authors
concluded that their findings could raise the prospect of
individualised therapy for these high-risk patients, this ap-
proach has not yet filtered through neither to routine clinical
practice, nor as part of any published clinical trial to date.
In a subsequent publication, the same group demonstrated
that expression signatures of T-cell co-stimulation/exhaustion
relate to outcomes in AAV [28]. Thus, they proposed that T-
cell exhaustion plays a central role in determining outcome in
autoimmune disease and targeted manipulation of this process
could lead to new therapeutic opportunities [28].
ANCA as a diagnostic biomarker
Although occasional cases of BANCA-negative^ AAVare ac-
knowledged, such patients represent the vast minority and are
encountered less commonly with improvements in ANCA
testing methodology (including using both indirect immuno-
fluorescence and enzyme-linked immunosorbent assay for
screening), such that in modern practice most clinicians would
be reluctant to make a firm diagnosis of AAV in the absence of
detectable ANCA.Moreover, it is increasingly recognised that
such BANCA-negative^ AAV patients have a broad differen-
tial diagnosis that may include entities such as chronic granu-
lomatous disease, IgG4 disease, monogenic granulomatous
diseases including Blau syndrome, or other immune-
mediated renal pathology. That said, there are anecdotal re-
ports of paediatric patients with vasculitis (particularly single
organ disease) who were initially ANCA negative, and who
subsequently became ANCA positive, suggesting that the
negative predictive value of ANCA testing for patients with
single organ disease at first presentation might be suboptimal
[29]. Thus, the diagnostic utility of ANCA as a biomarker for
AAV is largely irrefutable in the right clinical context, and
when positive are especially useful for those with atypical
presentations and/or single organ disease [30]. The fact that
ANCA positivity is usually a requirement for enrolment into
clinical trials involving patients with AAV [31], and is includ-
ed in paediatric classification criteria [32] and adult definitions
of AAV [33], may amplify the notion that a decreasing num-
ber of patients are ANCA negative, however.
ANCA as a biomarker of disease activity
Irrespective of their diagnostic utility, whether or not ANCAs
are useful to monitor disease activity has been long-debated
[34], and an area of controversy ever since ANCAs were first
discovered in 1982 [35]. In a study of 156 adult patients with
GPA, decreases in PR3-ANCA level were not associated with
a shorter time to remission, and increases were not associated
with relapse [36]. These observations led the authors to con-
clude that ANCA levels cannot be used to guide immunosup-
pressive therapy in patients with GPA [36]. Two more recent
studies agree with this conclusion overall, but suggested that
the serial testing of ANCAs might have specific utility for the
prediction of renal and/or pulmonary small vessel vasculitis
relapse, but not for granulomatous disease. Kemna et al. stud-
ied 166 adult patients with AAV, positive for either PR3-
ANCA or MPO-ANCA [37]. In this cohort, 104 patients
had renal involvement. After a follow-up of 49 (±33) months,
they observed that ANCA rises correlated with relapses in
patients who presented with renal involvement (hazard ratio
[HR], 11.09; 95% confidence interval [95% CI], 5.01 to
24.55), but in comparison, was only weakly associated with
relapses in patients who presented with non-renal disease
(HR, 2.79; 95% CI, 1.30 to 5.98) [37]. The authors concluded
that longitudinal ANCA measurements may be useful in pa-
tients with renal involvement, but less valuable in patients
with non-renal disease [37]. Even more recently, using data
generated from the Rituximab Versus Cyclophosphamide for
ANCA-associated Vasculitis (RAVE) trial, Fussner et al. eval-
uated the association of an increase in PR3-ANCAwith sub-
sequent relapse [38]. Although the authors found that an in-
crease in the PR3-ANCA titre was not a very sensitive or
specific predictor of subsequent relapse in general, they did
observe some association between an increase in PR3-ANCA
level and risk of subsequent relapse that was dependent on
specific factors. These were:
1. PR3-ANCA detection methodology (stronger association
for direct capture ELISA [hazard ratio 4.57], compared
with indirect ELISA)
2. Disease phenotype (renal vasculitis [HR 7.94], or alveolar
haemorrhage [HR 24.19], but not in those with a granu-
lomatous phenotype)
3. Choice of remission induction treatment (stronger associ-
ation for patients treated with rituximab as opposed to
cyclophosphamide/azathioprine) [38]
These findings support the view that PR3-ANCA pre-
dominantly affects capillaritis rather than granulomatous
inflammation, as highlighted in the accompanying edito-
rial to that study [34].
ANCA as a biomarker for choice of treatment
In another subsidiary study of the adult RAVE trial, Unizony
et al. evaluated whether the classification of adults with AAV
according to ANCA serotype predicted treatment response
[39]. PR3-AAV patients treated with rituximab achieved re-
mission at 6 months more frequently than patients treated with
cyclophosphamide followed by azathioprine (65 vs 48%;
p = 0.04; odds ratio [OR] 2.11, 95% CI 1.04 to 4.30).
Furthermore, PR3-AAV patients with relapsing disease
achieved remission more often following rituximab treatment
at 6 months (OR 3.57; 95% CI 1.43 to 8.93), 12 months (OR
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4.32; 95% CI 1.53 to 12.15) and 18months (OR 3.06; 95% CI
1.05 to 8.97). There was no association between treatment and
remission rates in patients with MPO-AAV, or in groups di-
vided according to AAV diagnosis (i.e. GPA vs MPA) [39].
This study suggested, therefore, that adult patients with PR3-
AAV respond better to rituximab than to conventional
induction/remission maintenance treatment with cyclophos-
phamide and azathioprine, and that ANCA serotype may
guide the type of treatment in AAV. Whether these findings
can be extrapolated to paediatric patients is uncertain, al-
though this may be explored when the results of the paediatric
polyangiitis rituximab study (PEPRS) are available (https://
clinicaltrials.gov/ct2/show/NCT01750697).
Biomarkers derived from studies of neutrophil activation
in AAV
A study by Hong et al. revealed insights into the pathogenesis
of AAV by studying ANCA–neutrophil interactions [22].
They observed that neutrophils stimulated either with poly-
clonal ANCA isolated from patients with AAV or chimeric
PR3-ANCA induced release of neutrophil microparticles
(NMPs). These NMPs expressed a variety of markers, includ-
ing the ANCA autoantigens PR3 and MPO. They bound en-
dothelial cells via a CD18-mediated mechanism; induced an
increase in endothelial intracellular adhesion molecule 1
(ICAM-1) expression and endothelial reactive oxygen species
(ROS); and stimulated the release of endothelial IL-6 and IL-
8. Removal of these NMPs by filtration abolished all these
aspects of endothelial activation. NMPs generated from
ANCA stimulation of primed neutrophils were also able to
generate thrombin. Last, more NMPs were detected in the
plasma of children with AAV compared with healthy controls
or those with inactive vasculitis. Taken together, these obser-
vations support a role for NMP in the pathogenesis of ANCA
vasculitis and could potentially suggest a target for therapeutic
plasma exchange in AAV [22], even though currently, their
clinical utility remains unvalidated.
Another novel aspect of neutrophil activation of relevance
to the pathogenesis of AAV (although not specific to AAV) are
neutrophil extracellular traps (NETs). These are chromatin
fibres released by ANCA-stimulated neutrophils, containing
antigenic components that include PR3 and MPO [40].
Kessenbrock et al. observed deposition of NETs in inflamed
kidneys, and suggested that NET formation might trigger vas-
culitis and promote the autoimmune response against neutro-
phil components in individuals with AAV [40]. It is increas-
ingly apparent that NETs may also be involved in various
other autoimmune diseases, including systemic lupus erythe-
matosus (SLE), and thus may offer insight into the pathogen-
esis of autoimmunity more generally, and possibly even a
novel therapeutic target [41]. More recently, however, Wang
et al. studied the potential of circulating NETs as biomarkers
of disease activity in adult patients with AAV (34 with active
disease, 62 in remission), and suggested that circulating levels
of NETSwere not useful for assessing disease activity in AAV
[42]. Although serum levels of NETs in active AAV patients
were higher than in healthy controls, there was no difference
in circulating NETs between patients with active vasculitis
and those in remission [42]. Differences in methodology for
NET detection may account in part for these seemingly con-
flicting observations. Thus, even though NETs may provide
insight into the pathogenesis of AAV, their potential as bio-
markers of disease activity in AAV has not yet been realised.
Urinary biomarkers of disease activity in AAV
Urinary biomarkers could provide an easily obtainable and
non-invasive means of monitoring renal vasculitis and other
renal pathology for children and adults, which, if reliable, may
obviate the need for repeat renal biopsy (the gold standard) in
patients suspected of having a renal flare of vasculitis [43].
Based on the observation that macrophage infiltration is im-
portant in the pathogenesis of glomerulonephritis in AAV,
Tam et al. investigated urinary monocyte chemoattractant pro-
tein 1 (MCP-1), and fractalkine as potential non-invasive bio-
markers for renal vasculitis in adults with AAV [44]. They
observed higher urinary MCP-1 levels in patients with active
renal vasculitis compared with healthy controls, patients with
inactive vasculitis, and patients with extra-renal vasculitis on-
ly. There were no differences in serum MCP-1 between these
patient groups and no differences in urinary fractalkine levels.
Reduction in urinary MCP-1 levels following treatment pre-
ceded the improvement of renal function by a median of
2 weeks; and in one patient, rising urinary levels of MCP-1
were associated with progression to severe renal failure de-
spite immunosuppression. The authors concluded that urinary
MCP-1 could offer a useful non-invasive biomarker for the
assessment of renal vasculitis, and for monitoring its treatment
[44].
Recently, O’Reilly et al. suggested that urinary soluble
CD163 (sCD163) may provide an even better biomarker of
renal vasculitis than urinary MCP-1 [45]. They performed a
thorough and in-depth study involving a rat model, adult pa-
tients with small vessel vasculitis (SVV: i.e. GPA, MPA,
EGPA, and anti-glomerular basement membrane disease),
healthy controls, and disease controls. Disease controls were
subdivided into those with and those without glomerulone-
phritis, and intensive care patients with non-immune-
mediated acute kidney injury, multisystem failure and sepsis.
They detected sCD163 in rat urine early in the disease course
of experimental vasculitis. Furthermore, micro-dissected glo-
meruli from patients with SVV had higher levels of CD163
mRNA expression than those with lupus nephritis, diabetic
nephropathy, or nephrotic syndrome, and there was strong
expression of CD163 protein in the glomeruli and interstitium
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of patients with SVV. Patients with SVV had markedly higher
urinary sCD163 than patients in remission, disease controls,
or healthy controls. These results were confirmed using both
internal and external validation cohorts. The authors suggest
that an optimal cut-off for urinary sCD163 0.3 ng/mmol cre-
atinine would detect active renal vasculitis with a sensitivity of
83%, specificity of 96%, and positive likelihood ratio of 20.8.
They concluded that this urinary biomarker could be useful for
monitoring disease activity in renal vasculitis in patients with
an already established diagnosis, but not necessarily for the
diagnosis of renal vasculitis in the first instance, as some of the
sepsis patients had high levels. They also highlighted that
urinary sCD163 is a highly stable protein in urine (stable for
at least a week at room temperature) and was better suited to
storage/transport than urinary MCP-1, which degrades quick-
ly [45]. Future studies should attempt to replicate these find-
ings in paediatric patients before this test can be used reliably
in children with renal vasculitis, however.
Other biomarkers and miscellaneous vasculitides:
endothelial injury and repair concept
Systemic vasculitis is characterised by systemic inflammation,
endothelial activation, and (in some cases) necrosis of blood
vessel walls, leading to multi-organ injury [24, 46].
Endothelial activation and injury are central to the pathogen-
esis, with increased endothelial cell adhesion molecule ex-
pression, and a switch to a prothrombotic endothelial pheno-
type, both of which contribute to the vascular pathology of
vasculitis [47, 48].
Two important biomarkers of endothelial injury are endo-
thelial microparticles (EMPs), and circulating detached ma-
ture endothelial cells (CECs). EMPs are released from the cell
surface in response to a variety of stimuli associated with
endothelial injury, including vasculitis and atherosclerosis
[49]. It has previously been demonstrated that endothelial in-
jury in vasculitis can be tracked through the detection of cir-
culating EMPs [49–52]. More recently, studies have revealed
that these EMPs may generate excess thrombin and thrombot-
ic complications in children with systemic vasculitis [53], ce-
rebral vasculitis of the young [54], and as mentioned above,
MPs may be an important target for therapeutic plasma ex-
change in AAV [22]. CECs are necrotic, highly activated en-
dothelial cells that detached from the vessel wall [55]. They
have been described as a biomarker of disease activity in vas-
culitis in adults [55] and children [50, 51], childhood stroke
caused by cerebral vasculitis [54], as a marker of coronary
injury years after Kawasaki disease (KD) [56], andmany other
clinical scenarios associated with endothelial injury.
In addition to this severe endothelial injury, it has been
suggested that endothelial repair processes may also be im-
paired in certain clinical scenarios [57, 58], and thus vasculitis
could be particularly damaging to the cardiovascular system
owing to an unfavourable imbalance between endothelial in-
jury and repair, as is the case in other diseases targeting the
endothelium [59, 60]. It is now known that recruitment of
bone marrow-derived endothelial progenitor cells (EPCs) rep-
resent an important mechanism of endothelial repair [61].
These EPCs may play an important role in endothelial main-
tenance and vascular healing in health and disease, and are
emerging as important biomarkers of prognosis in atheroscle-
rosis [62, 63]. As vascular dysfunction is an important late
sequela of vasculitis in children [64] and adults [65], recent
studies have focussed on the perturbation of endothelial repair
pathways. Zavada et al. observed a reduced number of endo-
thelial progenitor cells in adults with AAV, and found that they
were predictive of early relapse [66]. Intriguingly, and in con-
trast to this finding in adults, Clarke et al. observed numeri-
cally higher circulating levels of EPCs in children with active
vasculitis, suggesting that paediatric patients might be able to
mount a compensatory repair response to inflammatory endo-
thelial injury [51]. Hong et al. observed, however, that the
function of these elevated circulating EPCs was impaired in
children with active vasculitis [47]. Similar findings were ob-
served by Eleftheriou et al. in children with arterial stroke
caused by cerebral vasculitis [67].
Von Willebrand factor (VWF), a plasma protein synthe-
sised primarily by megakaryocytes and endothelial cells, me-
diates platelet aggregation and adhesion [68]. Levels increase
in response to endothelial injury or activation, and have been
described as a biomarker of disease activity in many vasculit-
ides including KD, HSP and AAV. Its performance as a bio-
marker of disease activity in childhood CNS vasculitis was
recently investigated. In a cohort study of 39 children with
childhood primary angiitis of the CNS, 65% had increased
levels at diagnosis, which decreased significantly after treat-
ment. The authors concluded that although these preliminary
results were encouraging, further studies are required to eval-
uate the sensitivity and specificity of VWF as a potential bio-
marker for disease activity in this context [68]. Indeed, another
study of children with cerebral vasculitis found VWF to be a
poor discriminator of disease activity [54]. More recently, a
study of VWF in adult patients with AAV and renal involve-
ment observed high levels of VWF in patients with active
vasculitis that persisted even when they were considered in
clinical remission [69]. This casts some doubt on the validity
of VWF as a robust biomarker of disease activity in AAV.
Moreover, whether elevation of VWF solely represents endo-
thelial activation or injury, or alternatively platelet activation
and/or activation of the clotting cascade, is debatable [69].
Thus, the endothelial injury and repair concept provides a
framework for studies that provide insight into the pathogen-
esis of systemic vasculitis and its sequelae. Even though in the
future this may provide useful biomarkers for monitoring dis-
ease activity, response to treatment, defining prognosis, or
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identify new therapeutic targets, these biomarkers (with the
exception of VWF) remain (at the moment) within the re-
search domain.
IgA vasculitis (Henoch–Schönlein purpura)
IgAV is one of the most common vasculitides of childhood
[70], and is of particular relevance to the paediatric nephrolo-
gy community. The clinical picture is characterised by non-
thrombocytopaenic purpura, arthritis and arthralgia, abdomi-
nal pain, gastrointestinal haemorrhage, and glomerulonephri-
tis. The American College of Rheumatology (ACR) classifi-
cation criteria [71] are now superseded by paediatric classifi-
cation criteria [32]. There has been a lack of progress in rela-
tion to understanding the pathogenesis of IgA vasculitis, and
therapeutic clinical trials, particularly for the associated glo-
merulonephritis. It is hoped that robust paediatric classifica-
tion criteria will facilitate future high-quality translatable re-
search to make progress in this area.
Pathogenesis of IgAV: genetic background
Several polymorphisms relating to disease susceptibility, se-
verity, and/or risk of renal involvement have been described.
Studies of this nature have been hampered by relatively small
patient numbers and thus lack the power to be definitive or
necessarily applicable to all racial groups. It is, however, in-
creasingly apparent that the genetic contribution is complex
and probably polygenic in nature, although familial clusters of
the disease may occur. Investigations from Spain have pre-
sented preliminary data on genetic associations. The frequen-
cy of HLA-B35 was increased in patients who developed
nephritis [72]. The incidence of HLA-DRB1∗01 was also in-
creased compared with matched controls, and HLA-
DRB1∗07 was decreased [73]. A study of unselected children
with IgAV from Turkey showed that HLA A2, A11 and B35
antigens were associated with a significantly increased risk of
IgAV, whereas HLA A1, B49 and B50 antigens were associ-
ated with a decreased risk of the disease [74]. There was no
association, however, with HLA class 1 alleles and renal in-
volvement [74]. Even though there were no general associa-
tions with the expression of intercellular adhesion molecule 1
in patients compared with controls, a K/E polymorphism at
codon 469 was significantly decreased in those who did not
develop severe gastrointestinal manifestations (and possibly
in patients without renal sequelae) [75]. In studies from
Israel and Turkey, mutations in the familial Mediterranean
fever (MEFV) gene were frequent in patients with IgAV [76,
77]. Other genetic polymorphisms have also been implicated,
and have been reviewed elsewhere [78].
Immunology of IgAV and potential biomarkers
Many reports have implicated infection, particularly with β-
haemolytic streptococci, as a potential trigger for this disease
[79–82]. Some investigators have, however, doubted this as-
sociation [83–85]. Other preceding immunological triggers,
including vaccination [86, 87] and viral infection [88–91],
have been described.
The characteristic vascular deposition of IgA strongly sug-
gests that IgAV might be a predominantly IgA-mediated dys-
regulated immune response to antigen and may operate
through the alternative complement pathway [92]. Although
the pathogenetic mechanisms of nephritis are still not delin-
eated, studies suggest that galactose-deficient IgA1 might be
recognised by antiglycan antibodies, leading to the formation
of circulating immune complexes and their mesangial deposi-
tion, which results in renal injury in IgAV [93]. An increase in
the levels of poorly galactosylated IgA1 appears insufficient
to cause IgAV nephritis or IgA nephropathy, as first-degree
relatives may have high serum levels of poorly galactosylated
IgA1, but no signs of nephritis [94, 95]. Thus, it is likely that a
Bsecond hit^ is required for high levels of poorly
galactosylated IgA1 to form immune complexes that result
in nephritis [95]. It is suggested that this second hit might be
the formation of antiglycan IgG or IgA antibodies (perhaps
triggered by infection), that then go on to form large circulat-
ing immune complexes with the poorly galactosylated IgA1,
which are prone to deposition [95]. Currently, the genes con-
trolling IgA1 glycosylation are unknown. Other factors that
may modulate IgA synthesis and galactosylation include B-
cell programming at the time of antigen encounter, Toll-like
receptor activation, and local cytokine production [95]. It has
been suggested that the genetic mechanisms controlling these
processes should be further explored to try to better under-
stand the genetic contribution to the pathogenesis of HSP
nephritis, and IgA nephropathy [95]. Thus, even though many
questions remain unanswered in relation to this pathogenetic
model, increased serum levels of poorly galactosylated IgA1
remain the most consistent finding in patients with IgAV ne-
phritis and IgA nephropathy, and these almost certainly pre-
dispose to the formation of IgA immune complexes with
resulting vasculitis.
Disorders of coagulation and its activation are also associ-
ated with the development of IgAV [96]. It is recognised that
disease activity may be linked to a rapid decline of factor XIII,
particularly in patients with severe abdominal involvement
[97–99]. This may be useful as a prognostic or diagnostic
biomarker because the decline occurs before classic skin rash
and thus could allow early diagnosis of IgAV, where abdom-
inal symptoms and signs predominate. There is no informa-
tion regarding the diagnostic specificity of a fall in factor XIII,
however. Anecdotal reports of factor XIII replacement to suc-
cessfully treat severe abdominal symptoms in IgAV are
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described [99], but no high-quality controlled data relating to
this treatment are available. Factor XIII also declines before
recurrence of IgAV; yet, it is unknown whether this is merely a
secondary epiphenomenon, or a true causative association.
Makay et al. recently suggested that an elevated circulating
neutrophil to lymphocyte ratio (NLR) might be a predictor of
gastrointestinal haemorrhage in children with IgAV [100].
This finding was not replicated in a separate study that exclud-
ed those already bleeding, which is of particular relevance as
acute haemorrhage is associated with neutrophilia [101].
Thus, the clinical utility of the NLR in IgAV is questionable.
Monogenic vasculitides: DADA2, CANDLE
and SAVI
Three recently described monogenic autoinflammatory condi-
tions with a major vasculitic component are worthy of a brief
description, as they highlight new pathophysiological path-
ways with potential for targeted treatment, provide new bio-
markers and serve to emphasise the concept that understand-
ing the molecular pathogenesis may lead to more targeted
therapy [102–105].
DADA2
Deficiency of adenosine deaminase type 2 (DADA2) is an
autosomal recessive disease resembling polyarteritis nodosa,
caused by homozygous or compound heterozygous mutations
in the CECR1 gene [102, 103]. The cardinal clinical features
include livedo racemosa, neurological involvement including
the propensity to lacunar (small vessel) stroke, vasculitic pe-
ripheral neuropathy, digital ischaemia and cutaneous ulcera-
tion, systemic inflammation, and other end organ damage
[102, 103, 106, 107]. There is an emerging view that anti-
TNF-alpha therapy is particularly efficacious for this form of
monogenic vasculitis [107]; this may be because the extracel-
lular enzyme ADA2 functions as an important regulator of
immune development. Patients with DADA2 demonstrate
skewed macrophage development towards the M1 pro-
inflammatory phenotype as opposed to the M2 anti-
inflammatory phenotype [102, 103]. M1 macrophages are
known to produce TNF-α, which could explain why this ther-
apeutic approach seems particularly effective in DADA2
[102, 103]. Allogeneic haematopoietic stem cell transplanta-
tion has been reported to be successful in a few patients [108];
gene therapy may be an option for the future [107].
In relation to a novel diagnostic biomarker for this form of
vasculitis, an obvious candidate would be serum or plasma
adenosine deaminase type 2 activity and/or levels. These as-
says are beginning to be established in some centres, although
mainly within the research domain at the moment. Thus far,
preliminary data indicate that healthy children have higher
ADA2 activity levels than adults, a fact that should be taken
into account when considering using this test as a diagnostic
biomarker for DADA2 [109]. In addition, ADA2 enzyme ac-
tivity appears not to change with disease activity, as pre-
symptomatic patients with confirmed genetic mutations in
CECR1 have low levels similar to those in patients with active
disease and patients in remission on treatment [109].
Even if molecular genetic testing becomes more widely
available for this disease, it will still be important to have
confirmatory ADA2 enzyme activity or a level assay to un-
derstand whether or not any novel genetic sequence variants
(Bvariants of unknown significance^) in CECR1 are truly
pathogenic. Thus, genetic screening for DADA2 should be
backed up with some assessment of ADA2 enzyme activity
and/or level before a firm clinical diagnosis can be established.
Validated methodologies with international and age-specific
standards will be important to establish full incorporation of
this biomarker into routine clinical care for children.
CANDLE and SAVI
Chronic atypical neutrophilic dermatosis with lipodystrophy
and elevated temperature (CANDLE) syndrome is a recessive
disease caused by homozygous, compound heterozygous or
digenic mutations in the proteasome pathway, and is classified
as a proteasome-associated autoinflammatory syndrome
(PRAAS) [105, 110]. Mutations in PSMB8, PSMB4,
PSMB9, PSMA3, and proteasome maturation protein
(POMP) are described [105, 110]. In the early stages, the
neutrophilic dermatosis may display the histological features
of neutrophilic/leucocytoclastic vasculitis. CANDLE is asso-
ciated with dysregulated type I interferon production; there-
fore, targeting this pathway with Janus kinase (JAK) inhibi-
tors may be a promising novel therapeutic approach [105,
110]. Early clinical trials of baricitinib, an oral JAK1 and
JAK2 inhibitor, are ongoing.
Stimulator of interferon genes (STING)-associated vascu-
litis of infancy (SAVI) arises from sporadic/dominant muta-
tion in the TMEM173 gene and presents early in life with a
vasculitic rash affecting the cheeks, nose and peripheries with
chronic ulceration; and progressive interstitial pulmonary fi-
brosis and associated pulmonary hypertension [104, 111].
Standard vasculitis therapies are ineffective. Cutaneous vas-
culitis and deteriorating lung function usually continue relent-
lessly throughout childhood, with development of pulmonary
hypertension and lung fibrosis, often with fatal outcome [104,
111]. SAVI is considered part of the growing group of
Mendelian disorders recognised as Binterferonopathies,^
which include Aicardi–Goutières syndrome (AGS), and the
aforementioned CANDLE syndrome [112]. Although virtual-
ly no published data are currently available, anecdotal reports
again suggest that early treatment targeting the interferon
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pathway (e.g. with JAK inhibitors) might currently offer the
best hope for survival.
Gene expression profiles (an Binterferon score^) can be
used to screen for suspected interferonopathies, and thus can
be exploited as diagnostic screening biomarkers to guide ge-
netic screening and/or interpretation [113]. Interferon gene
expression profiles could also be used as a biomarker to guide
choice of therapy (e.g. JAK inhibition versus more conven-
tional vasculitis treatment), and to monitor disease activity in
response to therapy [113]. Again, a few centres are beginning
to establish this approach, but at the moment this is mainly still
being researched and is not yet widely available.
Conclusion
Considerable progress has been made in understanding the
pathogenesis of vasculitis, and consequently promising bio-
marker discoveries. Despite this, it should be remembered that
primary outcome measures in clinical trials of vasculitis re-
main clinical, such as the paediatric vasculitis activity score
[114] and its adult equivalent. In particular, novel diagnostic
tests, particularly for monogenic forms of vasculitis, which
can be screened for using next-generation sequencing targeted
gene panels, are highlighted, as these particular monogenic
forms of vasculitis have significant therapeutic implications,
and demonstrate that an understanding of the molecular basis
of vasculitis can identify new therapeutic pathways, new bio-
markers and new treatments.
Compliance with ethical standards
Conflict of interest The authors declare that they have no conflicts of
interest.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. Eleftheriou D, Brogan PA (2016) Therapeutic advances in the
treatment of vasculitis. Pediatr Rheumatol 14:26
2. Ntatsaki E, Carruthers D, Chakravarty K, D’Cruz D, Harper L,
Jayne D, Luqmani R, Mills J, Mooney J, Venning M, Watts RA
(2014) BSR and BHPR guideline for the management of adults
with ANCA-associated vasculitis. Rheumatology (Oxford) 53:
2306–2309
3. Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T,
Hellmich B, Holle JU, LaudienM, Little MA, Luqmani RA,Mahr
A, Merkel PA, Mills J, Mooney J, Segelmark M, Tesar V,
Westman K, Vaglio A, Yalcindag N, Jayne DR, Mukhtyar C
(2016) EULAR/ERA-EDTA recommendations for the
management of ANCA-associated vasculitis. Ann Rheum Dis
75:1583–1594
4. Biomarkers Definitions Working Group (2001) Biomarkers and
surrogate endpoints: preferred definitions and conceptual frame-
work. Clin Pharmacol Ther 69:89–95
5. Eleftheriou D, Batu ED, Ozen S, Brogan PA (2015) Vasculitis in
children. Nephrol Dial Transplant 30 [Suppl 1]:i94–i103
6. Eleftheriou D, Gale H, Pilkington C, FentonM, Sebire NJ, Brogan
PA (2016) Eosinophilic granulomatosis with polyangiitis in child-
hood: retrospective experience from a tertiary referral centre in the
UK. Rheumatology (Oxford) 55:1263–1272
7. Brogan P, Eleftheriou D, Dillon M (2010) Small vessel vasculitis.
Pediatr Nephrol 25:1025–1035
8. Belostotsky VM, Shah V, DillonMJ (2002) Clinical features in 17
paediatric patients with Wegener granulomatosis. Pediatr Nephrol
17:754–761
9. Akikusa JD, Schneider R, Harvey EA, Hebert D, Thorner PS,
Laxer RM, Silverman ED (2007) Clinical features and outcome
of pediatric Wegener’s granulomatosis. Arthritis Rheum 57:837–
844
10. Cabral DA, Uribe AG, Benseler S, O’Neil KM, Hashkes PJ,
Higgins G, Zeft AS, Lovell DJ, Kingsbury DJ, Stevens A
(2009) Classification, presentation, and initial treatment of
Wegener’s granulomatosis in childhood. Arthritis Rheum 60:
3413–3424
11. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman
GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK,
Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D,
Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB,
Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA,
Peikert T, Stegeman C, Ytterberg SR, Specks U (2010)
Rituximab versus cyclophosphamide for ANCA-associated vas-
culitis. N Engl J Med 363:221–232
12. Hilhorst M, Wilde B, van Paassen P, Winkens B, van Breda VP,
Tervaert JWC (2013) Improved outcome in anti-neutrophil cyto-
plasmic antibody (ANCA)-associated glomerulonephritis: a 30-
year follow-up study. Nephrol Dial Transplant 28:373–379
13. Bohm M, Fernandez MIG, Ozen S, Pistorio A, Dolezalova P,
Brogan P, Barbano G, Sengler C, Klein-Gitelman M, Quartier P
(2014) Clinical features of childhood granulomatosis with poly-
angiitis (Wegener’s granulomatosis). Pediatr Rheumatol 12:1–5
14. Guillevin L, Durand-Gasselin B, Cevallos R, GayraudM, Lhote F,
Callard P, Amouroux J, Casassus P, Jarrousse B (1999)
Microscopic polyangiitis. Arthritis Rheum 42:421–430
15. Pendergraft WF III, Nachman PH (2015) Recent pathogenetic
advances in ANCA-associated vasculitis. Presse Med 44:e223–
e229
16. Bansal PJ, Tobin MC (2004) Neonatal microscopic polyangiitis
secondary to transfer of maternal myeloperoxidase-antineutrophil
cytoplasmic antibody resulting in neonatal pulmonary hemorrhage
and renal involvement. Ann Allergy Asthma Immunol 93:398–
401
17. Schlieben DJ, Korbet SM, Kimura RE, Schwartz MM, Lewis EJ
(2005) Pulmonary-renal syndrome in a newborn with placental
transmission of ANCAs. Am J Kidney Dis 45:758–761
18. Xiao H, Heeringa P, Hu P, Liu Z, Zhao M, Aratani Y, Maeda N,
Falk RJ, Jennette JC (2002) Antineutrophil cytoplasmic autoanti-
bodies specific for myeloperoxidase cause glomerulonephritis and
vasculitis in mice. J Clin Invest 110:955–963
19. Little MA, Al-Ani B, Ren S, Al-Nuaimi H, Leite M Jr, Alpers CE,
Savage CO, Duffield JS (2012) Anti-proteinase 3 anti-neutrophil
cytoplasm autoantibodies recapitulate systemic vasculitis in mice
with a humanized immune system. PLoS One 7, e28626
20. Jennette JC, Xiao H, Falk RJ (2006) Pathogenesis of vascular
inflammation by anti-neutrophil cytoplasmic antibodies. J Am
Soc Nephrol 17:1235–1242
Pediatr Nephrol (2018) 33:187–198 195
21. Morgan MD, Harper L, Williams J, Savage C (2006) Anti-
neutrophil cytoplasm-associated glomerulonephritis. J Am Soc
Nephrol 17:1224–1234
22. Hong Y, Eleftheriou D, Hussain AA, Price-Kuehne FE, Savage
CO, Jayne D, LittleMA, SalamaAD, Klein NJ, Brogan PA (2012)
Anti-neutrophil cytoplasmic antibodies stimulate release of neu-
trophil microparticles. J Am Soc Nephrol 23:49–62
23. Mulder AH, Stegeman CA, Kallenberg CG (1995) Activation of
granulocytes by anti-neutrophil cytoplasmic antibodies (ANCA)
in Wegener’s granulomatosis: a predominant role for the IgG3
subclass of ANCA. Clin Exp Immunol 101:227–232
24. Brogan PA (2007) What’s new in the aetiopathogenesis of vascu-
litis? Pediatr Nephrol 22:1083–1094
25. Lyons PA, Rayner TF, Trivedi S, Holle JU, Watts RA, Jayne DR,
Baslund B, Brenchley P, Bruchfeld A, Chaudhry AN, Cohen
Tervaert JW, Deloukas P, Feighery C, Gross WL, Guillevin L,
Gunnarsson I, Harper L, Hruskova Z, Little MA, Martorana D,
Neumann T, Ohlsson S, Padmanabhan S, Pusey CD, Salama AD,
Sanders JS, Savage CO, Segelmark M, Stegeman CA, Tesar V,
Vaglio A, Wieczorek S, Wilde B, Zwerina J, Rees AJ, Clayton
DG, Smith KG (2012) Genetically distinct subsets within ANCA-
associated vasculitis. N Engl J Med 367:214–223
26. Carr EJ, Niederer HA,Williams J, Harper L,Watts RA, Lyons PA,
Smith KG (2009) Confirmation of the genetic association of
CTLA4 and PTPN22 with ANCA-associated vasculitis. BMC
Med Genet 10:121
27. McKinney EF, Lyons PA, Carr EJ, Hollis JL, JayneDR,Willcocks
LC, Koukoulaki M, Brazma A, Jovanovic V, Kemeny DM,
Pollard AJ, Macary PA, Chaudhry AN, Smith KG (2010) A
CD8+ T cell transcription signature predicts prognosis in autoim-
mune disease. Nat Med 16:586–591, 1p following 591
28. McKinney EF, Lee JC, Jayne DR, Lyons PA, Smith KG (2015) T-
cell exhaustion, co-stimulation and clinical outcome in autoimmu-
nity and infection. Nature 523:612–616
29. Arulkumaran N, Jawad S, Smith SW, Harper L, Brogan P, Pusey
CD, Salama AD (2011) Long- term outcome of paediatric patients
with ANCAvasculitis. Pediatr Rheumatol 9:12
30. Iglesias E, Eleftheriou D, Mankad K, Prabhakar P, Brogan PA
(2014) Microscopic polyangiitis presenting with hemorrhagic
stroke. J Child Neurol 29:NP1–NP4
31. Jayne D, Rasmussen N (2015) Twenty-five years of European
Union collaboration in ANCA-associated vasculitis research.
Nephrol Dial Transplant 30 [Suppl 1]:i1–i7
32. Ozen S, Pistorio A, Iusan SM, Bakkaloglu A, Herlin T, Brik R,
Buoncompagni A, Lazar C, Bilge I, Uziel Y, Rigante D, Cantarini
L, Hilario MO, Silva CA, Alegria M, Norambuena X, Belot A,
Berkun Y, Estrella AI, Olivieri AN, Alpigiani MG, Rumba I,
Sztajnbok F, Tambic-Bukovac L, Breda L, al-Mayouf S,
Mihaylova D, Chasnyk V, Sengler C, Klein-Gitelman M, Djeddi
D, Nuno L, Pruunsild C, Brunner J, Kondi A, Pagava K, Pederzoli
S, Martini A, Ruperto N (2010) EULAR/PRINTO/PRES criteria
for Henoch-Schonlein purpura, childhood polyarteritis nodosa,
childhoodWegener granulomatosis and childhood Takayasu arter-
itis: Ankara 2008. II. Final classification criteria. Ann Rheum Dis
69:798–806
33. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F,
Flores-Suarez LF, Gross WL, Guillevin L, Hagen EC, Hoffman
GS, Jayne DR, Kallenberg CG, Lamprecht P, Langford CA,
Luqmani RA, Mahr AD, Matteson EL, Merkel PA, Ozen S,
Pusey CD, Rasmussen N, Rees AJ, Scott DG, Specks U, Stone
JH, Takahashi K, Watts RA (2013) 2012 revised International
Chapel Hill Consensus Conference Nomenclature of
Vasculitides. Arthritis Rheum 65:1–11
34. Koh JH, Kemna MJ, Cohen Tervaert JW, Kim WU (2016)
Editorial: Can an increase in antineutrophil cytoplasmic
autoantibody titer predict relapses in antineutrophil cytoplasmic
antibody-associated vasculitis? Arthritis Rheumatol 68:1571–
1573
35. Davies DJ, Moran JE, Niall JF, Ryan GB (1982) Segmental
necrotising glomerulonephritis with antineutrophil antibody: pos-
sible arbovirus aetiology? Br Med J (Clin Res Ed) 285:606
36. Finkielman JD, Merkel PA, Schroeder D, Hoffman GS, Spiera R,
St Clair EW, Davis JC Jr, McCune WJ, Lears AK, Ytterberg SR,
Hummel AM, Viss MA, Peikert T, Stone JH, Specks U (2007)
Antiproteinase 3 antineutrophil cytoplasmic antibodies and dis-
ease activity in Wegener granulomatosis. Ann Intern Med 147:
611–619
37. Kemna MJ, Damoiseaux J, Austen J, Winkens B, Peters J, van
Paassen P, Cohen Tervaert JW (2015) ANCA as a predictor of
relapse: useful in patients with renal involvement but not in pa-
tients with nonrenal disease. J Am Soc Nephrol 26:537–542
38. Fussner LA, Hummel AM, Schroeder DR, Silva F, Cartin-Ceba R,
Snyder MR, Hoffman GS, Kallenberg CG, Langford CA, Merkel
PA, Monach PA, Seo P, Spiera RF, William St CE, Tchao NK,
Stone JH, Specks U (2016) Factors determining the clinical utility
of serial measurements of antineutrophil cytoplasmic antibodies
targeting proteinase 3. Arthritis Rheumatol 68:1700–1710
39. Unizony S, Villarreal M, Miloslavsky EM, Lu N, Merkel PA,
Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CM, St
Clair EW, Ikle D, Tchao NK, Ding L, Brunetta P, Choi HK,
Monach PA, Fervenza F, Stone JH, Specks U (2016) Clinical
outcomes of treatment of anti-neutrophil cytoplasmic antibody
(ANCA)-associated vasculitis based on ANCA type. Ann
Rheum Dis 75:1166–1169
40. Kessenbrock K, Krumbholz M, Schonermarck U, Back W, Gross
WL, Werb Z, Grone HJ, Brinkmann V, Jenne DE (2009) Netting
neutrophils in autoimmune small-vessel vasculitis. Nat Med 15:
623–625
41. Barnado A, Crofford LJ, Oates JC (2016) At the bedside: neutro-
phil extracellular traps (NETs) as targets for biomarkers and ther-
apies in autoimmune diseases. J Leukoc Biol 99:265–278
42. Wang H, Sha LL, Ma TT, Zhang LX, Chen M, Zhao MH (2016)
Circulating level of neutrophil extracellular traps is not a useful
biomarker for assessing disease activity in antineutrophil cytoplas-
mic antibody-associated vasculitis. PLoS One 11, e0148197
43. Free ME, Falk RJ (2016) The search for a biomarker of relapse in
ANCA-associated vasculitis. J Am Soc Nephrol 27:2551–2553
44. Tam FW, Sanders JS, George A, Hammad T, Miller C, Dougan T,
Cook HT, Kallenberg CG, Gaskin G, Levy JB, Pusey CD (2004)
Urinary monocyte chemoattractant protein-1 (MCP-1) is a marker
of active renal vasculitis. Nephrol Dial Transplant 19:2761–2768
45. O’Reilly VP, Wong L, Kennedy C, Elliot LA, O’Meachair S,
Coughlan AM, O’Brien EC, Ryan MM, Sandoval D, Connolly
E, Dekkema GJ, Lau J, Abdulahad WH, Sanders JS, Heeringa P,
Buckley C, O’Brien C, Finn S, Cohen CD, Lindemeyer MT,
Hickey FB, O’Hara PV, Feighery C, Moran SM, Mellotte G,
Clarkson MR, Dorman AJ, Murray PT, Little MA (2016)
Urinary soluble CD163 in active renal vasculitis. J Am Soc
Nephrol 27:2906–2916
46. Dillon MJ, Eleftheriou D, Brogan PA (2010) Medium-size-vessel
vasculitis. Pediatr Nephrol 25:1641–1652
47. Hong Y, Eleftheriou D, Klein NJ, Brogan PA (2015) Impaired
function of endothelial progenitor cells in children with primary
systemic vasculitis. Arthritis Res Ther 17:292
48. Tomasson G, Monach PA, Merkel PA (2009) Thromboembolic
disease in vasculitis. Curr Opin Rheumatol 21:41–46
49. Brogan PA, Dillon MJ (2004) Endothelial microparticles and the
diagnosis of the vasculitides. Intern Med 43:1115–1119
50. Clarke LA, Shah V, Arrigoni F, Eleftheriou D, Hong Y, Halcox J,
Klein N, Brogan PA (2008) Quantitative detection of circulating
endothelial cells in vasculitis: comparison of flow cytometry and
196 Pediatr Nephrol (2018) 33:187–198
immunomagnetic bead extraction. J Thromb Haemost 6:1025–
1032
51. Clarke LA, Hong Y, Eleftheriou D, Shah V, Arrigoni F, Klein NJ,
Brogan PA (2010) Endothelial injury and repair in systemic vas-
culitis of the young. Arthritis Rheum 62:1770–1780
52. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T,
Woywodt A, Haller H, Haubitz M (2008) Diagnostic role of en-
dothelial microparticles in vasculitis. Rheumatology (Oxford) 47:
1820–1825
53. Eleftheriou D, Hong Y, Klein NJ, Brogan PA (2011)
Thromboembolic disease in systemic vasculitis is associated with
enhanced microparticle-mediated thrombin generation. J Thromb
Haemost 9:1864–1867
54. Eleftheriou D, Ganesan V, Hong Y, Klein NJ, Brogan PA (2012)
Endothelial injury in childhood strokewith cerebral arteriopathy: a
cross-sectional study. Neurology 79:2089–2096
55. Woywodt A, Streiber F, de Groot K, Regelsberger H, Haller H,
Haubitz M (2003) Circulating endothelial cells as markers for
ANCA-associated small-vessel vasculitis. Lancet 361:206–210
56. Shah V, Christov G, Mukasa T, Brogan KS, Wade A, Eleftheriou
D, LevinM, Tulloh RM,Almeida B, DillonMJ,Marek J, Klein N,
Brogan PA (2015) Cardiovascular status after Kawasaki disease in
the UK. Heart 101:1646–1655
57. Choi JH, Kim KL, Huh W, Kim B, Byun J, Suh W, Sung J, Jeon
ES, Oh HY, Kim DK (2004) Decreased number and impaired
angiogenic function of endothelial progenitor cells in patients with
chronic renal failure. Arterioscler Thromb Vasc Biol 24:1246–
1252
58. Mohan S, Barsalou J, Bradley TJ, Slorach C, Reynolds JA, Hasni
S, Thompson B, Ng L, Levy D, Silverman E, Kaplan MJ (2015)
Endothelial progenitor cell phenotype and function are impaired in
childhood-onset systemic lupus erythematosus. Arthritis
Rheumatol 67:2257–2262
59. Dimmeler S, Zeiher AM (2004) Vascular repair by circulating
endothelial progenitor cells: the missing link in atherosclerosis?
J Mol Med 82:671–677
60. Sabatier F, Camoin-Jau L, Anfosso F, Sampol J, Dignat-George F
(2009) Circulating endothelial cells, microparticles and progeni-
tors: key players towards the definition of vascular competence. J
Cell Mol Med 13:454–471
61. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee
R, Li T, Witzenbichler B, Schatteman G, Isner JM (1997)
Isolation of putative progenitor endothelial cells for angio-
genesis. Science 275:964–967
62. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA,
Quyyumi AA, Finkel T (2003) Circulating endothelial progenitor
cells, vascular function, and cardiovascular risk. N Engl J Med
348:593–600
63. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A,
Bohm M, Nickenig G (2005) Circulating endothelial progenitor
cells and cardiovascular outcomes. N Engl J Med 353:999–1007
64. Cheung YF, Brogan PA, Pilla CB, Dillon MJ, Redington AN
(2002) Arterial distensibility in children and teenagers: normal
evolution and the effect of childhood vasculitis. Arch Dis Child
87:348–351
65. Mukhtyar C, Brogan P, Luqmani R (2009) Cardiovascular in-
volvement in primary systemic vasculitis. Best Pract Res Clin
Rheumatol 23:419–428
66. Zavada J, Kideryova L, Pytlik R, Hruskova Z, Tesar V (2009)
Reduced number of endothelial progenitor cells is predictive of
early relapse in anti-neutrophil cytoplasmic antibody-associated
vasculitis. Rheumatology (Oxford) 48:1197–1201
67. Eleftheriou D, Ganesan V, Hong Y, Klein NJ, Brogan PA (2015)
Endothelial repair in childhood arterial ischaemic stroke with ce-
rebral arteriopathy. Cerebrovasc Dis Extra 5:68–74
68. Cellucci T, Tyrrell PN, Pullenayegum E, Benseler SM (2012) Von
Willebrand factor antigen—a possible biomarker of disease activ-
ity in childhood central nervous system vasculitis? Rheumatology
(Oxford) 51:1838–1845
69. Salmela A, Ekstrand A, Joutsi-Korhonen L, Raisanen-Sokolowski
A, Lassila R (2015) Activation of endothelium, coagulation and
fibrinolysis is enhanced and associates with renal anti-neutrophil
cytoplasmic antibody-associated vasculitis. Nephrol Dial
Transplant 30[Suppl 1]:i53–i59
70. Gardner-Medwin JM, Dolezalova P, Cummins C, Southwood TR
(2002) Incidence of Henoch-Schonlein purpura, Kawasaki dis-
ease, and rare vasculitides in children of different ethnic origins.
Lancet 360:1197–1202
71. Mills JA, Michel BA, Bloch DA, Calabrese LH, Hunder GG,
Arend WP, Edworthy SM, Fauci AS, Leavitt RY, Lie JT (1990)
The American College of Rheumatology 1990 criteria for the
classification of Henoch-Schonlein purpura. Arthritis Rheum 33:
1114–1121
72. Amoli MM, ThomsonW, Hajeer AH, CalvinoMC, Garcia-Porrua
C, Ollier WE, Gonzalez-Gay MA (2002) HLA-B35 association
with nephritis in Henoch-Schonlein purpura. J Rheumatol 29:
948–949
73. Amoli MM, ThomsonW, Hajeer AH, CalvinoMC, Garcia-Porrua
C, Ollier WE, Gonzalez-Gay MA (2001) HLA-DRB1*01 associ-
ation with Henoch-Schonlein purpura in patients from northwest
Spain. J Rheumatol 28:1266–1270
74. Peru H, Soylemezoglu O, Gonen S, Cetinyurek A, Bakkaloglu
SA, Buyan N, Hasanoglu E (2008) HLA class 1 associations in
Henoch Schonlein purpura: increased and decreased frequencies.
Clin Rheumatol 27:5–10
75. Amoli MM, Mattey DL, Calvino MC, Garcia-Porrua C, Thomson
W, Hajeer AH, Ollier WE, Gonzalez-Gay MA (2001)
Polymorphism at codon 469 of the intercellular adhesion
molecule-1 locus is associated with protection against severe gas-
trointestinal complications in Henoch-Schonlein purpura. J
Rheumatol 28:1014–1018
76. Gershoni-Baruch R, Broza Y, Brik R (2003) Prevalence and sig-
nificance of mutations in the familial Mediterranean fever gene in
Henoch-Schonlein purpura. J Pediatr 143:658–661
77. Ozcakar ZB, Yalcinkaya F, Cakar N, Acar B, Kasapcopur O,
Uguten D, Soy D, Kara N, Uncu N, Arisoy N, Ekim M (2008)
MEFV mutations modify the clinical presentation of Henoch-
Schonlein purpura. J Rheumatol 35:2427–2429
78. Eleftheriou D, Brogan PA (2012) Themolecular biology and treat-
ment of childhood systemic vasculitis. In: Homeister JW, Willis
MS (eds) Molecular and translational vascular medicine, 1st edn.
Springer, New York, pp 35–70
79. Al-Sheyyab M, Batieha A, el-Shanti H, Daoud A (1999) Henoch-
Schonlein purpura and streptococcal infection: a prospective case–
control study. Ann Trop Paediatr 19:253–255
80. Allen DM, Diamond LK, Howell DA (1960) Anaphylactoid pur-
pura in children (Schonlein-Henoch syndrome): review with a
follow-up of the renal complications. AMA J Dis Child 99:833–
854
81. Gairdner D (1948) The Schonlein-Henoch syndrome (anaphylac-
toid purpura). Q J Med 17:95–122
82. Masuda M, Nakanishi K, Yoshizawa N, Iijima K, Yoshikawa N
(2003) Group A streptococcal antigen in the glomeruli of children
with Henoch-Schonlein nephritis. Am J Kidney Dis 41:366–370
83. Atkinson SR, Barker DJ (1976) Seasonal distribution of Henoch-
Schonlein purpura. Br J Prev Soc Med 30:22–25
84. Levy M, Broyer M, Arsan A, Levy-Bentolila D, Habib R
(1976) Anaphylactoid purpura nephritis in childhood: natural
history and immunopathology. Adv Nephrol Necker Hosp 6:
183–228
Pediatr Nephrol (2018) 33:187–198 197
85. Matsukura H, Ohtsuki A, Fuchizawa T, Miyawaki T (2003) Acute
poststreptococcal glomerulonephritis mimicking Henoch-
Schonlein purpura. Clin Nephrol 59:64–65
86. Courtney PA, Patterson RN, Lee RJ (2001) Henoch-Schonlein
purpura following meningitis C vaccination. Rheumatology
(Oxford) 40:345–346
87. Lambert EM, Liebling A, Glusac E, Antaya RJ (2003) Henoch-
Schonlein purpura following a meningococcal vaccine. Pediatrics
112, e491
88. Eisenstein EM (2002) Lack of evidence for herpesvirus, retrovi-
rus, or parvovirus infection in Henoch-Schonlein purpura. Clin
Exp Rheumatol 20:734
89. Heegaard ED, Taaning EB (2002) Parvovirus B19 and parvovirus
V9 are not associatedwith Henoch- Schonlein purpura in children.
Pediatr Infect Dis J 21:31–34
90. Minohara Y (1995) Studies on the relationship between anaphy-
lactoid purpura and human parvovirus B19. Kansenshogaku
Zasshi 69:928–933
91. Watanabe T, Oda Y (2000) Henoch-Schonlein purpura nephritis
associated with human parvovirus B19 infection. Pediatr Int 42:
94–96
92. Giangiacomo J, Tsai CC (1977) Dermal and glomerular deposition
of IgA in anaphylactoid purpura. Am J Dis Child 131:981–983
93. Lau KK, Suzuki H, Novak J, Wyatt RJ (2010) Pathogenesis of
Henoch-Schonlein purpura nephritis. Pediatr Nephrol 25:19–26
94. Kiryluk K, Moldoveanu Z, Sanders JT, Eison TM, Suzuki H,
Julian BA, Novak J, Gharavi AG, Wyatt RJ (2011) Aberrant gly-
cosylation of IgA1 is inherited in both pediatric IgA nephropathy
and Henoch-Schonlein purpura nephritis. Kidney Int 80:79–87
95. Boyd JK, Barratt J (2011) Inherited IgA glycosylation pattern in
IgA nephropathy and HSP nephritis: where do we go next?
Kidney Int 80:8–10
96. Brendel-Muller K, Hahn A, Schneppenheim R, Santer R (2001)
Laboratory signs of activated coagulation are common in Henoch-
Schonlein purpura. Pediatr Nephrol 16:1084–1088
97 . Gunaseka ran TS, Berman J , Gonza lez M (2000 )
Duodenojejunitis: is it idiopathic or is it Henoch-Schonlein pur-
pura without the purpura? J Pediatr Gastroenterol Nutr 30:22–28
98. Kamitsuji H, Tani K, Yasui M, Taniguchi A, Taira K, Tsukada S,
Iida Y, Kanki H, Fukui H (1987) Activity of blood coagulation
factor XIII as a prognostic indicator in patients with Henoch-
Schonlein purpura. Efficacy of factor XIII substitution. Eur J
Pediatr 146:519–523
99. Kawasaki K, Komura H, Nakahara Y, Shiraishi M, Higashida M,
Ouchi K (2006) Factor XIII in Henoch-Schonlein purpura with
isolated gastrointestinal symptoms. Pediatr Int 48:413–415
100. Makay B, Gucenmez OA, Duman M, Unsal E (2014) The
relationship of neutrophil-to-lymphocyte ratio with gastroin-
testinal bleeding in Henoch-Schonlein purpura. Rheumatol
Int 34:1323–1327
101. Ozturk K, Ekinci Z (2016) Is neutrophil-to-lymphocyte ratio valid
to predict organ involvement in Henoch-Schonlein purpura?
Rheumatol Int 36:1147–1148
102. Zhou Q, Yang D, Ombrello AK, Zavialov AV, Toro C, Zavialov
AV, Stone DL, Chae JJ, Rosenzweig SD, Bishop K (2014) Early-
onset stroke and vasculopathy associated with mutations in
ADA2. N Engl J Med 370:911–920
103. Navon Elkan P, Pierce SB, Segel R, Walsh T, Barash J, Padeh S,
Zlotogorski A, Berkun Y, Press JJ, Mukamel M (2014) Mutant
adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N
Engl J Med 370:921–931
104. Liu Y, Jesus AA, Marrero B, Yang D, Ramsey SE, Montealegre
Sanchez GA, Tenbrock K, Wittkowski H, Jones OY, Kuehn HS
(2014) Activated STING in a vascular and pulmonary syndrome.
N Engl J Med 371:507–518
105. Liu Y, Ramot Y, Torrelo A, Paller AS, Si N, Babay S, Kim PW,
Sheikh A, Lee CCR, Chen Y (2012) Mutations in PSMB8 cause
CANDLE syndrome with evidence of genetic and phenotypic
heterogeneity. Arthritis Rheum 64:895
106. Batu ED, Karadag O, Taskiran EZ, Kalyoncu U, Aksentijevich I,
Alikasifoglu M, S Ö (2015) A case series of adenosine deaminase
2-deficient patients emphasizing treatment and genotype-
phenotype correlations. J Rheumatol 42:1532–1534
107. Nanthapisal S, Murphy C, Omoyinmi E, Standing A, Hong Y,
Gomes SM, Klein N, Eleftheriou D, Brogan PA (2015)
Monogenic polyarteritis nodosa caused by ADA2 deficiency: the
GOSH experience. Pediatr Rheumatol 13:8
108. VanMontfrans J, Zavialov A, Zhou Q, ZhouQ, Yang D, Ombrello
AK (2014) Mutant ADA2 in vasculopathies. N Engl J Med 2014:
478–481
109. Nanthapisal S, Murphy C, Omoyinmi E, Hong Y, Standing A,
Berg S, Ekelund M, Jolles S, Harper L, Youngstein T, Gilmour
K, Klein NJ, Eleftheriou D, Brogan PA (2016) Deficiency of
adenosine deaminase type 2: a description of phenotype and ge-
notype in fifteen cases. Arthritis Rheumatol 68:2314–2322
110. Brehm A, Liu Y, Sheikh A, Marrero B, Omoyinmi E, Zhou Q,
Montealegre G, Biancotto A, Reinhardt A, de Jesus AA (2015)
Additive loss-of-function proteasome subunit mutations in
CANDLE/PRAAS patients promote type I IFN production. J
Clin Invest 125:4196–4211
111. Omoyinmi E, Melo Gomes S, Nanthapisal S, Woo P, Standing A,
Eleftheriou D, Klein N, Brogan PA (2015) Stimulator of interferon
genes-associated vasculitis of infancy. Arthritis Rheumatol 67:808
112. Crow YJ (2011) Type I interferonopathies: a novel set of inborn
errors of immunity. Ann N YAcad Sci 1238:91–98
113. Volpi S, Picco P, Caorsi R, Candotti F, Gattorno M (2016) Type I
interferonopathies in pediatric rheumatology. Pediatr Rheumatol
14:35
114. Dolezalova P, Price-Kuehne FE, Ozen S, Benseler SM, Cabral
DA, Anton J, Brunner J, Cimaz R, O’Neil KM, Wallace CA,
Wilkinson N, Eleftheriou D, Demirkaya E, Bohm M, Krol P,
Luqmani RA, Brogan PA (2013) Disease activity assessment in
childhood vasculitis: development and preliminary validation of
the Paediatric Vasculitis Activity Score (PVAS). Ann Rheum Dis
72:1628–1633
198 Pediatr Nephrol (2018) 33:187–198
